ArticleScience progress
Cystatin C is a potential biomarker for predicting hyperhomocysteinemia associated with chronic kidney disease
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectiveHyperhomocysteinemia (HHCY) is regarded as a significant risk factor for both fatal and non-fatal cardiovascular incidents in chronic kidney disease (CKD) patients. The objective of this research was to investigate the association between cystatin C (CYSC) and HHCY in individuals diagnosed with CKD.MethodsRetrospective cross-sectional study was conducted on clinical data and laboratory data of 85 individuals with CKD. The patients were divided into two distinct groups according to a threshold homocysteine (HCY) level of 15 µmol·L-1: the normal HCY group consisting of 40 cases, and the high HCY group (HHCY) comprising 45 cases. Moreover, the correlation between CYSC and HCY was examined. The correlation between CYSC and HCY was assessed. To further validate this relationship, HCY levels were measured in the culture medium following CYSC overexpression and silencing in vitro.ResultsOur study found that CYSC levels were significantly elevated in CKD-associated HHCY patients compared to CKD patients without concurrent HHCY (p < 0.05). CYSC and HCY showed a positive correlation (p < 0.05). CYSC was determined to be an Independent risk factor for CKD-associated HHCY. In vitro experiments have demonstrated that elevated levels of HCY were observed in the culture supernatants from OE-CYSC mesangial cells compared with the control and OE-negative control groups (p < 0.05). Conversely, the opposite trend occurs.ConclusionsIn conclusion, the findings suggest that CYSC may be the potential to serve as a biomarker to detect high HCY levels associated with CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.